Activities of Garenoxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 3, 2004, Pages 765-773

  Azoulay Dupuis, E ^a   Bedos J P ^a   Mohler, J ^a   Peytavin, G ^a   Isturiz, R ^a   Moine, P ^a   Rieux, V ^a   Cherbuliez, C ^b   Pechere J C ^b   Fantin, B ^a   Kohler T ^b  

^a INSERM   (France)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ETHIDIUM BROMIDE; GARENOXACIN; MOXIFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; CONTROLLED STUDY; DRUG POTENCY; GYRA GENE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PARC GENE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

EID: 10744230244     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.3.765-773.2004     Document Type: Article

References (25)

1. Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15:77-83.
2. Appelbaum, P. C. 1996. Emergence of resistance to antimicrobial agents in gram-positive bacteria-pneumococci. Drugs 51(Suppl. 1):1-5.
3. Azoulay-Dupuis, E., E. Vallée, B. Veber, J. P. Bédos, J. Bauchet, and J. J. Pocidalo. 1992. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob. Agents Chemother. 36:2698-2703.
4. Bédos, J. P., V. Rieux, J. Bauchet, M. Muffat-Joly, C. Carbon, and E. Azoulay-Dupuis. 1998. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob. Agents Chemother. 42:862-867.
5. Boswell, F. J., J. M. Andrews, and R. Wise. 2001. Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae. J. Antimicrob. Chemother. 48:446-447.
6. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
7. Clark, C. L., K. Nagai, T. A. Davies, B. Bozdogan, B. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 2002. Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin. Clin. Microbiol. Infect. 8:373-380.
8. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
9. Gales, A., H. Sader, R. N. Jones, and SENTRY Participants Group (Latin America). 2001. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY Antimicrobial Surveillance Program medical centers in Latin America (1999). Antimicrob. Agents Chemother. 45:1463-1466.
10. Hartman-Neumann, S., K. DenBleyker, L. A. Pelosi, L. E. Lawrence, J. F. Barrett, and T. J. Dougherty. 2001. Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756. Antimicrob. Agents Chemother. 45:2865-2870.
11. Hyatt, J. M., D. E. Nix, and J. J. Schentag. 1994. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob. Agents Chemother. 38:2730-2737.
12. Janoir, C., V. Zeller, M. Kitzis, N. J. Moreau, and L. Gutman. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
13. Jones, R. N., M. A. Pfaller, M. Stilwell, and the SENTRY Antimicrobial Surveillance Program Participants Group. 2001. Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant gram-positive cocci. Diagn. Microbiol. Infect. Dis. 39:133-135.
14. Lawrence, L. E., P. Wu, L. Fan, K. E. Gouveia, A. Card, M. Casperson, K. DenBleyker, and J. F. Barrett. 2001. The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues. J. Antimicrob. Chemother. 48:195-201.
15. Lieberman, D., F. Schlaeffer, H. Boldur, D. Lieberman, S. Horowitz, M. Leinonen, O. Horowitz, E. Manor, and A. Porath. 1996. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 51:179-184.
16. Moine, P., J. B. Vercken, S. Chevret, C. Chastang, P. Gajdos, and the French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. 1994. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. Chest 105:1487-1495.
17. Munoz, R., and A. G. De La Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
18. National Committee for Clinical Laboratory Standards. 2000. Performance standards for antimicrobial disk susceptibility tests; approved standard, 7th ed., M2-A7, vol. 20, no. 1. National Committee for Clinical Laboratory Standards, Wayne, Pa.
19. Pallarés, R., J. Linarés, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich, R. Martin, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:474-480.
20. Pan, X. S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471-474.
21. Piddock, L. J., M. Johnson, and S. L. Hill. 1998. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob. Agents Chemother. 42:2956-2960.
22. Reinert, R. R., A. Al-Lahham, R. Lütticken, M. Boos, and F. J. Schmitz. 2002. Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones. J. Antimicrob. Chemother. 49:1015-1018.
23. Schmitz, F. J., M. Boos, H. Jagusch, S. Mayer, A. C. Fluit, and D. Hafner. 2001. Induction of in vitro resistance to BMS-284756 by Streptococcus pneumoniae. J. Antimicrob. Chemother. 48:588-590.
24. Teng, R., D. Girard, T. D. Gootz, G. Foulds, and T. E. Liston. 1996. Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs and monkeys. Antimicrob. Agents Chemother. 40:561-566.
25. Zeller, V., C. Janoir, M. Kitzis, L. Gutmann, and N. J. Moreau. 1997. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1973-1978.